Siponimod
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive Multiple Sclerosis patients
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive Multiple Sclerosis patients
NUI Galway are looking for people to take part in a new programme
Queens researchers in £2 million bid to reverse the damage of Multiple Sclerosis
The UCD School of Medicine is delighted to partner with MS Ireland in order to expand our Patient Educator Programme, which currently involves educators that were recruited with the help of Arthritis Ireland and the Irish Society for Colitis and Crohn’s Disease.
© 2010 - 2026 Multiple Sclerosis Society of Ireland